Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women

Marleen Kars,1 Ling Yang,2 Margaret F. Gregor,2 B. Selma Mohammed,1 Terri A. Pietka,1 Brian N. Finck,1 Bruce W. Patterson,1 Jay D. Horton,3 Bettina Mittendorfer,1 Gökhan S. Hotamisligil,2 and Samuel Klein1

OBJECTIVE—Insulin resistance is commonly associated with obesity. Studies conducted in obese mouse models found that endoplasmic reticulum (ER) stress contributes to insulin resistance, and treatment with tauroursodeoxycholic acid (TUDCA), a bile acid derivative that acts as a chemical chaperone to enhance protein folding and ameliorate ER stress, increases insulin sensitivity. The purpose of this study was to determine the effect of TUDCA therapy on multiorgan insulin action and metabolic factors associated with insulin resistance in obese men and women.

RESEARCH DESIGN AND METHODS—Twenty obese subjects (means ± SD aged 48 ± 11 years, BMI 37 ± 4 kg/m²) were randomized to 4 weeks of treatment with TUDCA (1,750 mg/day) or placebo. A two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labeled tracer infusions and muscle and adipose tissue biopsies were used to evaluate in vivo insulin sensitivity, cellular factors involved in insulin signaling, and cellular markers of ER stress.

RESULTS—Hepatic and muscle insulin sensitivity increased by ~30% (P < 0.05) after treatment with TUDCA but did not change after placebo therapy. In addition, therapy with TUDCA, but not placebo, increased muscle insulin signaling (phosphorylated insulin receptor substrate Tyr and AktSer473 levels) (P < 0.05). Markers of ER stress in muscle or adipose tissue did not change after treatment with either TUDCA or placebo.

CONCLUSIONS—These data demonstrate that TUDCA might be an effective pharmacological approach for treating insulin resistance. Additional studies are needed to evaluate the target cells and mechanisms responsible for this effect. Diabetes 59: 1899–1905, 2010

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

From the 1Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, Washington University School of Medicine, St. Louis, Missouri; the 2Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts; and the 3Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

Corresponding author: Samuel Klein, sklein@wustl.edu.

Received 2 March 2010 and accepted 21 May 2010. Published ahead of print at http://diabetes.diabetesjournals.org on 3 June 2010. DOI: 10.2337/db10-0308. Clinical Trials reg. no. NCT00771901, clinicaltrials.gov. © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
insulin-resistant, obese subjects to evaluate the effect of treatment with TUDCA on insulin sensitivity in the liver (glucose production), muscle (glucose uptake), and adipose tissue (lipolysis). We hypothesized that treatment with TUDCA would improve multigorgan insulin signaling and sensitivity and other metabolic factors associated with insulin resistance. The hyperinsulinemic-euglycemic clamp procedure, in conjunction with stable isotope labeled tracer infusions, was used to determine in vivo insulin sensitivity, and adipose tissue and skeletal muscle biopsies were obtained to assess ER stress markers, phosphorylation of JNK, and components of the insulin-signaling pathway before and after 4 weeks of treatment with TUDCA or placebo.

**RESEARCH DESIGN AND METHODS**

Twenty obese adults (16 males, 38 females) aged 18–11 years, BMI 37 ± 4 kg/m² participated in this single-blinded, randomized, placebo-controlled trial. All subjects were insulin resistant, defined as a homeostasis model assessment of insulin resistance (HOMA-IR) value of ≥3.0 at the time of screening (24). Subjects completed a comprehensive medical evaluation, including a detailed history, physical examination, blood tests, and a 2-h oral glucose tolerance test in those who had diabetes. Chronic liver disease other than nonalcoholic fatty liver disease (NAFLD), severe hypertriglyceridemia (fasting triglyceride concentrations >400 mg/dl), and those who smoked cigarettes were taking medications known to alter glucose or lipid metabolism were excluded. We purposely studied obese subjects who were insulin resistant but did not have diabetes to provide the best chance for detecting an improvement in insulin sensitivity by TUDCA therapy, without the potential confounding influences of treatment with diabetes medications and differences in glucose control among study subjects. All subjects were sedentary (regular exercise <1 h/week and ≤1 time/week) and weight stable (<2% weight change) for at least 3 months before the study. Subjects provided written informed consent before participating in this study, which was approved by human research protection office of Washington University School of Medicine in St. Louis, Missouri.

**Body composition.** Body composition analyses were performed ~1 week before the hyperinsulinemic-euglycemic clamp procedure was performed. Body fat mass and fat-free mass were determined by using dual-energy X-ray absorptiometry (QDR 4500; Hologic, Waltham, MA). Abdominal subcutaneous adipose tissue and intra-abdominal adipose tissue volumes were determined by using magnetic resonance imaging; the sum of 10 axial images of 1-cm thickness beginning at the L4–L5 interspace and extending proximally, was used to determine each fat depot volume. Intrahepatic triglyceride content was determined by using magnetic resonance spectroscopy (3T Siemens Magnetom Trio scanner; Siemens, Erlanger, Germany); three 15 × 15–15-mm voxels were examined in each subject, and the values were averaged to provide an estimate of the percent of total liver volume comprised of triglyceride.

**Hyperinsulinemic-euglycemic clamp procedure.** Subjects were admitted to the clinical research unit at Washington University School of Medicine in the afternoon on the day before the clamp procedure. At 1800 h, they consumed a standard meal containing 12 kcal/kg fat-free mass, with 55% of total energy provided as carbohydrates, 30% as fat, and 15% as protein. Subjects then fasted, except for water, until completion of the clamp procedure the next day. At 0500 h the following morning, a catheter was inserted into a forearm vein to infuse stable isotope labeled tracers (purchased from Cambridge Isotope Laboratories, Andover, MA), dextrose and insulin. A second catheter was inserted into the contralateral radial artery to obtain blood samples. Radial artery cannulation was not successful in four subjects. Subjects then fasted, except for water, until completion of the clamp procedure. At 0930 h, 3.5 h after starting stage 1 of the clamp procedure to determine the levels and the extent of phosphorylation of JNK and elements of the insulin-signaling pathway. The biopsy sites were cleaned and draped, and the skin and underlying tissues were anesthetized with lidocaine. A small (≈0.5 cm) skin incision was made with a scalpel; adipose tissue was aspirated through a 4-mm liposuction cannula, and muscle tissue was obtained by using Tilley-Henkel forceps (Sontec Instruments, Centennial, CO). Muscle and adipose tissue biopsies were immediately rinsed in ice-cold saline, frozen in liquid nitrogen, and stored at −80° C until final analyses were performed.

**Intervention.** After the baseline clamp procedure was completed, each subject was randomized to 4 weeks of oral treatment with either TUDCA (1,750 mg/day) or placebo. Both TUDCA and placebo were kindly provided by Bruschettili S.R.L (Genova, Italy). During the 4-week intervention period, subjects were seen every week to review any study-related issues, reinforce treatment compliance, check body weight, and assess vital signs. After 4 weeks of treatment, the body composition analyses and clamp procedure performed at baseline were repeated. Stage 2 of the clamp procedure was not completed in 2 of 10 subjects who received TUDCA treatment because of technical difficulties in obtaining blood samples. Treatment with drug or placebo was continued for the duration of the study.

**Sample processing and analyses.** Plasma glucose concentration was determined by using an automated glucose analyzer (YSI 2300 STAT Plus; Yellow Springs Instruments, Yellow Springs, OH). Plasma FFA concentrations were quantified by using gas chromatography (HP 5890 Series II GC; Hewlett-Packard, Palo Alto, CA) (28). Plasma insulin concentration was measured by immunometric assay (R&D Systems, Minneapolis, MN). Total and high-molecular weight adiponectin concentrations were determined by using fast protein liquid chromatography (AKTA FPLC system; GE Healthcare) and fluorescent Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously described (30). Plasma glucose and palmitate tracer-to-tracer ratios were determined by using gas chromatography/mass spectroscopy (MSD 5973 system with capillary column; Hewlett-Packard), as previously described (30).

To determine the activation of the insulin signaling and the JNK pathways in muscle and adipose tissue, we measured the site-specific phosphorylation of insulin receptor substrate (IRS)-1, Akt, and JNK. Tissue samples were cryopulverized, and the powdered tissue transferred to a tube containing cell lysis solution (Cell Signaling, Beverly, MA) and homogenized using a polytron (PowerGen 125; Fisher, Pittsburgh, PA). Homogenates were spun at 15 min at 2000 g at 4°C to pellet insoluble material. The total protein concentration in the supernatant was measured (DC Protein Assay; Bio-Rad, Hercules, CA) (28). Plasma C-reactive protein and interleukin-6 concentrations were measured by using commercially available high-sensitivity immunoenzymoassays (R&D Systems, Minneapolis, MN). Total and high-molecular weight adiponectin concentrations were determined by using fast protein liquid chromatography (AKTA FPLC system; GE Healthcare) and fluorescent Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously described (30). Products, Los Angeles, CA). Plasma C-reactive protein and interleukin-6 concentrations were measured by using commercially available high-sensitivity immunoenzymoassays (R&D Systems, Minneapolis, MN). Total and high-molecular weight adiponectin concentrations were determined by using fast protein liquid chromatography (AKTA FPLC system; GE Healthcare) and fluorescent Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously described (30). Products, Los Angeles, CA). Plasma C-reactive protein and interleukin-6 concentrations were measured by using commercially available high-sensitivity immunoenzymoassays (R&D Systems, Minneapolis, MN). Total and high-molecular weight adiponectin concentrations were determined by using fast protein liquid chromatography (AKTA FPLC system; GE Healthcare) and fluorescent Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously described (30). Products, Los Angeles, CA). Plasma C-reactive protein and interleukin-6 concentrations were measured by using commercially available high-sensitivity immunoenzymoassays (R&D Systems, Minneapolis, MN). Total and high-molecular weight adiponectin concentrations were determined by using fast protein liquid chromatography (AKTA FPLC system; GE Healthcare) and fluorescent Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously described (30).
TABLE 1
Subjects’ characteristics, metabolic variables, and body composition

|                        | Placebo Before | Placebo After | TUDCA Before | TUDCA After |
|------------------------|----------------|---------------|--------------|-------------|
| n (male/female)        | 10 (4/6)       | —             | 10 (4/6)     | —           |
| Age (years)            | 49 ± 14        | —             | 47 ± 9       | —           |
| BMI (kg/m²)            | 37 ± 5         | 38 ± 5        | 35 ± 3       | 35 ± 3      |
| Total body mass (kg)   | 109 ± 18       | 110 ± 17      | 100 ± 12     | 100 ± 12    |
| Fat mass (%)           | 39 ± 7         | 39 ± 7        | 39 ± 8       | 39 ± 8      |
| Subcutaneous abdominal fat volume (cm³) | 5,087 ± 1,749 | 4,999 ± 1,672 | 4,803 ± 1,202 | 4,716 ± 1,188 |
| Intra-abdominal fat volume (cm³) | 2,146 ± 789 | 2,172 ± 716 | 2,724 ± 846 | 2,818 ± 924 |
| IHTG content (%)       | 14.0 ± 10.7    | 13.7 ± 9.6    | 8.2 ± 5.5    | 9.3 ± 7.2   |
| HOMA-IR                | 4.2 ± 1.8      | 4.3 ± 1.7     | 4.4 ± 2.7    | 3.8 ± 3.4   |

Plasma concentrations

|                        | Before | After |
|------------------------|--------|-------|
| Glucose (mg/dl)        | 97 ± 9 | 97 ± 10 |
| Insulin (µU/ml)        | 18 ± 7 | 18 ± 7 |
| FFAs (mmol/l)          | 0.59 ± 0.13 | 0.63 ± 0.15 |
| Triglycerides (mg/dl)  | 154 ± 52 | 145 ± 77 |
| AST (IU/l)             | 25.9 ± 10.3 | 27.9 ± 14.5 |
| ALT (IU/l)             | 30.3 ± 24.7 | 35.6 ± 34.9 |
| CRP (mg/l)             | 5.67 ± 5.60 | 5.90 ± 3.87 |
| IL-6 (pg/ml)           | 2.60 ± 0.95 | 2.44 ± 0.86 |
| Total adiponectin (mg/l) | 6.7 ± 3.8 | 6.9 ± 4.6 |
| HMW adiponectin (mg/l) | 2.2 ± 2.6 | 2.2 ± 2.9 |

Data are means ± SD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; HMW, high molecular weight; IL, interleukin.

RESULTS
Subject characteristics, metabolic variables, and body composition. Subjects randomized to receive TUDCA and placebo were similar in age, sex, BMI, and body composition (Table 1). Body weight, total body fat, and fat distribution (intra-abdominal fat volume and IHTG content) did not change after 4 weeks of treatment with either TUDCA or placebo (Table 1). Baseline (before treatment) plasma concentrations of glucose, insulin, FFAs, triglycerides, aspartate aminotransferase, alanine aminotransferase, total adiponectin, high–molecular weight adiponectin, and markers of inflammation were not different between groups and did not change after either TUDCA or placebo treatment (Table 1). The HOMA-IR score did not change after placebo treatment but was ~20% lower after TUDCA treatment (Table 1); however, the decrease in HOMA-IR after TUDCA therapy was not statistically significant.

Insulin sensitivity assessed by using the hyperinsulinemic-euglycemic clamp technique. During the hyperinsulinemic-euglycemic clamp procedure, euglycemia was maintained at ~100 mg/dl in all subjects (average plasma glucose concentration: 100.0 ± 2.1 mg/dl during stage 1 and 102.0 ± 2.7 mg/dl during stage 2 of the clamp procedure) and plasma insulin concentration increased to

by using nonparametric analyses. A P value ≤0.05 was considered statistically significant. Results are reported as means ± SD (normally distributed datasets) or medians and quartiles (skewed datasets).

Based on data on glucose kinetics we obtained in obese subjects previously (33), we estimated that a sample size of 10 participants per group would allow us to detect a 25% difference in insulin sensitivity after treatment between groups, with a n of 0.65 and power of 80% (β = 0.2). A difference in insulin sensitivity of this magnitude is clinically meaningful because it represents the lower end of the observed effect of current treatment strategies for insulin resistance, such as moderate weight loss (33) or pharmacotherapy (e.g., metformin and thiazolidinediones) (34–41).

antibodies tagged with red (anti-mouse) or green (anti-rabbit) fluorophores. Detection was performed with the LiCor dual-color system (Li-Cor Biosciences, Lincoln, NE). All band intensities were visualized and quantified by using the LiCor system and Odyssey 3.0 software, and phosphorylation levels were expressed as a function of total protein levels.

Real-time quantitative PCR was performed as previously described to determine the mRNA expression of ER stress markers (glucose-regulated protein 78 [Grp78], spliced X-box binding protein-1 [XBP-1], and C/EBP homologous protein [CHOP]) in adipose tissue (22). Frozen adipose tissue samples were homogenized in TRizol reagent (Invitrogen, Carlsbad, CA), and cDNA synthesis was performed by using 1 µg of sample RNA reverse transcribed with high-capacity cDNA archive system (Applied Biosystems, Foster City, CA); quantitative RT-PCR was performed by using SybrGreen reagent in an ABI 7300 real-time PCR system (Applied Biosystems). The mRNA expression of ER stress markers were normalized to 18S rRNA. The protein expression of homocysteine-induced ER protein (HERP) and the concentrations of eukaryotic elongation initiation factor 2α (eIF2α) phosphorylated at serine 51 and JNK phosphorylated at threonine 183 and tyrosine 185 in adipose tissue were determined by Western analyses using rabbit polyclonal anti-p-eIF2α (Invitrogen) and mouse monoclonal anti-p-JNK (Cell Signaling, Danvers, MA) antibodies as previously described (22). Anti-HERP antibody was a gift from Dr. Yasuhiko Hirabayashi of Tohoku University (Sendai Japan). The band intensities of p-eIF2α, p-JNK, and HERP were normalized to actin.

Calculations. Isotopic steady-state conditions were achieved during the final 30 min of the basal period and stages 1 and 2 of the clamp procedure, so the Steele equation for steady-state conditions was used to calculate glucose rate of appearance (Rg), glucose rate of disappearance (Rd), and palmitate Rd (31). The hepatic insulin sensitivity index was determined as the reciprocal of the hepatic insulin resistance index, which was calculated as the product of the basal hepatic glucose production rate (in µmol/min) and basal plasma insulin concentration (in µU/ml) (32). Adipose tissue insulin sensitivity was assessed by calculating the relative decrease from basal in palmitate Rd into plasma during stage 1 of the clamp procedure. Skeletal muscle insulin sensitivity was assessed by calculating the relative increase from basal in glucose Rd from plasma during stage 2 of the clamp procedure. The HOMA-IR score was calculated as the product of fasting plasma insulin (in mU/l) and glucose (in mmol/l) concentrations divided by 22.5 (24).

Statistical analyses. Statistical analyses were performed by using SPSS for Windows (version 16.0; SPSS, Chicago, IL). Results are reported as means ± SD (normally distributed datasets) or medians and quartiles (skewed datasets). Two-way repeated-measures ANOVA was used to determine whether the changes in outcomes (normally distributed datasets) in response to either TUDCA or placebo treatment were different. Skewed data sets were evaluated...
The hepatic insulin sensitivity index increased by ~30% after TUDCA treatment but was not affected by placebo therapy (Fig. 1A). Glucose $R_d$ increased by ~150% ($P < 0.001$) from basal values during stage 2 of the clamp procedure in both the TUDCA and placebo groups before treatment. Compared with baseline (pretreatment) values, the increase in glucose $R_d$ above basal values during stage 2 was 34 ± 23% greater after treatment with TUDCA ($P < 0.05$) but did not change after treatment with placebo (Fig. 1B). Insulin infusion suppressed palmitate $R_a$ by ~50% in both TUDCA and placebo groups before treatment, and this remained the same after treatment with either TUDCA or placebo (Fig. 1C).

Consistent with our kinetic data, TUDCA therapy increased insulin signaling in muscle but not adipose tissue. Compared with placebo treatment, TUDCA treatment increased insulin-stimulated phosphorylation of IRS$_{Tyr}$ and Akt$_{Ser473}$ in muscle (both $P < 0.05$) (Fig. 2). In contrast, TUDCA therapy did not alter insulin-stimulated phosphorylation of IRS$_{Tyr}$ and Akt$_{Ser473}$ in adipose tissue (data not shown). No difference in skeletal muscle phosphorylation of JNK$_{Thr183/Tyr185}$ was detected between subjects treated with placebo or TUDCA (Fig. 2).

**ER stress markers in muscle and adipose tissue.** Adipose tissue mRNA expression of spliced XBP-1, Grp78, and CHOP (Fig. 3A) and protein levels of HERP, eIF2α$_{Ser52}$, and JNK$_{Thr183/Tyr185}$ (Fig. 3B) were not affected by either placebo or TUDCA treatment. Spliced XBP-1, Grp78, and CHOP mRNA expression in skeletal muscle were very low (below the limit of reliable detection for spliced XBP-1) and did not change after TUDCA treatment (data not shown).
sensitivity in liver, muscle, and adipose tissue (18). However, the use of agents that can decrease ER stress to treat obesity-associated insulin resistance has not been evaluated in people. Accordingly, we conducted a randomized controlled trial to determine the effect of 4 weeks of treatment with TUDCA on multiorgan insulin sensitivity and factors involved in regulating insulin action in obese subjects with insulin resistance. Our data demonstrate that TUDCA therapy increases hepatic and muscle insulin action in vivo with a concomitant increase in the phosphorylation of components of the muscle insulin-signaling pathway. Moreover, the magnitude of the improvement in hepatic and muscle insulin sensitivity (both ~30%) is similar to the insulin-sensitizing effects of currently available diabetes medications, such as thiazolidinediones and metformin (35–41). However, we did not detect an effect of TUDCA on adipose tissue insulin sensitivity or ER stress, making it unlikely that a reduction in adipocyte ER stress was responsible for the effect on insulin action in this trial. These data suggest that TUDCA therapy might provide a novel pharmacological approach for improving glucose homoeostasis in insulin-resistant obese people.

The precise cellular mechanisms responsible for the improvement in hepatic insulin sensitivity after TUDCA therapy are not clear. Data from studies conducted in human hepatocyte cultures have shown that TUDCA activates Akt and its downstream targets via a G-protein–coupled receptor–dependent mechanism (42,43). In addition, activation of the nuclear farnesoid X receptor (FXR) by bile acids or FXR agonists improves insulin sensitivity in vitro in cell systems and in vivo in animal models (44,45). However, TUDCA, unlike some other bile acids, is a relatively poor substrate for FXR (46). In animal models and cultured liver cells, TUDCA treatment can suppress ER stress and increase insulin signaling (18). Therefore, it is possible that TUDCA therapy affected hepatic ER stress in our subjects, but we did not obtain liver tissue in our subjects to directly evaluate this possibility.

The mechanisms responsible for the TUDCA-induced improvement in skeletal muscle insulin sensitivity and insulin signaling in our subjects and in the previous study (18) conducted in mice are also not clear. In contrast with adipose tissue and liver, ER stress indicators are not increased in skeletal muscle from obese mice (15,18) or obese people (23), and TUDCA treatment did not affect muscle ER stress markers in our study. In addition, muscle does not express the FXR (46), which precludes the possibility of an FXR-mediated improvement in muscle insulin action. However, G-protein receptors are expressed ubiquitously, so some of the effects of TUDCA in muscle might be mediated by G-protein receptor activation of Akt.

Although we found that TUDCA therapy improved hepatic and muscle insulin sensitivity, we did not find a significant effect of TUDCA therapy on HOMA-IR and many of the metabolic variables associated with insulin resistance, such as plasma glucose, insulin, and FFA concentrations. It is likely that these measures were not adequate to detect an effect of TUDCA, which required a more sensitive assessment of insulin action by using stable isotopically labeled tracers and the hyperinsulinemic-euglycemic clamp procedure.

Unlike data obtained from mouse models (18), we did not detect an effect of TUDCA therapy on adipose tissue insulin sensitivity or signaling or the expression of adipose tissue ER stress markers. Several factors might be responsible for the apparent difference observed after TUDCA therapy in mice and our study in human subjects. First, it is possible that the amount of TUDCA we gave our subjects, which is the maximum dose used to treat biliary disease, was insufficient to generate changes in adipose tissue ER stress; in the previous study, ~30 times more TUDCA relative to body weight was given to mice than to our subjects. Second, TUDCA was given intraperitoneally in the mice but orally to our subjects. It is likely this difference in route of administration further limited the systemic availability of TUDCA in our subjects, because TUDCA is effectively metabolized by the liver and there is minimal splanchic escape of bile acid conjugates into the systemic circulation (47). Finally, the expression of transporters responsible for TUDCA tissue uptake is very low in most extrahepatic tissues (48,49), so large plasma concentrations might be needed to achieve adequate tissue uptake to affect intracellular function. These pharmacokinetic factors raise the possibility that adipose tissue did not get sufficient exposure to orally administered TUDCA to affect ER stress in our subjects. Future studies with different dosing regimens are needed to address this issue.

In summary, insulin resistance is involved in the pathogenesis of the key metabolic disorders associated with obesity (1–3,6–14). The results from the present study demonstrate that TUDCA therapy increases liver and muscle insulin sensitivity in obese, insulin-resistant subjects. Additional studies are needed to determine the specific cellular mechanisms responsible for this effect and to determine the therapeutic potential of this class of compounds for obese people with insulin resistance.

ACKNOWLEDGMENTS

This study was supported by National Institutes of Health Grants DK 37948, DK52539, DK 56341 (Nutrition Obesity Research Center), RR 00954 (Biomedical Mass Spectrometry Resource), ULI RR024992 (Institute for Clinical and Translational Science), and T32 ES007155-24 (Environmental Health Training grant). This study also received support from the Nutricia Research Foundation (2009-26), Syndexa Pharmaceuticals, a mentor-based postdoctoral fellowship from the American Diabetes Association, and a Donald and Sue Pritzker Scholar award.

G.S.H. is a shareholder and member of the scientific advisory board at Syndexa Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

M.K., B.M., G.S.H., and S.K. were involved in designing and conducting the infusion studies, processing the study samples, collecting data, performing the final data analyses, and writing the manuscript. B.S.M. was involved in conducting the infusion studies. M.F.G., L.Y., T.A.P., B.N.F., B.W.P., and J.D.H. were involved in sample processing and sample analyses.

The authors thank Adewole Okunade, Freida Custodio, and Jennifer Shew for their technical assistance, Ken Schechtman for assistance with statistical analyses, Melissa Moore and the staff of the Clinical Research Unit for their help in performing the studies, and the study subjects for their participation.

diabetes.diabetesjournals.org
REFERENCES
1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Mannin R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923
2. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145–1151
3. Adham AA, Lemp SA, Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121
4. Ferrannini E, Natali P, Bello P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997;100:1166–1173
5. Esteghamati A, Khalizadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A. Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res 2008;39:868–869
6. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, Cline GW, Pongratz RL, Zhang XM, Chi CO, Coleman RA, Shulman GI. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2005;2:55–65
7. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisser JG, Bhanoit S, Monia BP, Shulman GI. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by anti-sense oligonucleotide inhibitors of acyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116:817–824
8. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2006;134:1369–1375
9. Deivanayagam S, Mohammed BS, Vitola BE, Naguib GH, Keshen TH, Kirk EP. Klein S. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr 2008;88:257–263
10. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Gastaldelli A, Cremasco F, Bardini G, Pierazzuoli C, Mencucci A, Pierazzuoli C. FXR activation reverses metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res 2008;39:868–869
11. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Cipriani S, Mencarelli A, Palladino G, Fiorucci S. 45. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A. 44. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A. 43. Chrousos GP, Halasz A, Hales CN, Shen Y, Mannucci E, Ognibene A, Cremasco F, Bardini G, Pierazzuoli C, Mencucci A, Pierazzuoli C. 42. Chrousos GP, Halasz A, Hales CN, Shen Y, Mannucci E, Ognibene A, Cremasco F, Bardini G, Pierazzuoli C, Mencucci A, Pierazzuoli C. 41. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli C, Mencucci A, Pierazzuoli C. 40. Cipriani S, Mencarelli A, Palladino G, Fiorucci S, F. Conjugated bile acids regulate hepatocyte glycogen synthase activity and plasma free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023–3028
49. TUDCA AND INSULIN ACTION
50. 48. TUDCA AND INSULIN ACTION
51. 47. TUDCA AND INSULIN ACTION
52. 46. TUDCA AND INSULIN ACTION
53. 45. TUDCA AND INSULIN ACTION
54. 44. TUDCA AND INSULIN ACTION
55. 43. TUDCA AND INSULIN ACTION
56. 42. TUDCA AND INSULIN ACTION
57. 41. TUDCA AND INSULIN ACTION
58. 40. TUDCA AND INSULIN ACTION
59. 39. TUDCA AND INSULIN ACTION
60. 38. TUDCA AND INSULIN ACTION
61. 37. TUDCA AND INSULIN ACTION
62. 36. TUDCA AND INSULIN ACTION
63. 35. TUDCA AND INSULIN ACTION
64. 34. TUDCA AND INSULIN ACTION
65. 33. TUDCA AND INSULIN ACTION
66. 32. TUDCA AND INSULIN ACTION
67. 31. TUDCA AND INSULIN ACTION
68. 30. TUDCA AND INSULIN ACTION
69. 29. TUDCA AND INSULIN ACTION
70. 28. TUDCA AND INSULIN ACTION
71. 27. TUDCA AND INSULIN ACTION
72. 26. TUDCA AND INSULIN ACTION
73. 25. TUDCA AND INSULIN ACTION
74. 24. TUDCA AND INSULIN ACTION
75. 23. TUDCA AND INSULIN ACTION
76. 22. TUDCA AND INSULIN ACTION
77. 21. TUDCA AND INSULIN ACTION
78. 20. TUDCA AND INSULIN ACTION
79. 19. TUDCA AND INSULIN ACTION
80. 18. TUDCA AND INSULIN ACTION
81. 17. TUDCA AND INSULIN ACTION
82. 16. TUDCA AND INSULIN ACTION
83. 15. TUDCA AND INSULIN ACTION
84. 14. TUDCA AND INSULIN ACTION
85. 13. TUDCA AND INSULIN ACTION
86. 12. TUDCA AND INSULIN ACTION
87. 11. TUDCA AND INSULIN ACTION
88. 10. TUDCA AND INSULIN ACTION
89. 9. TUDCA AND INSULIN ACTION
90. 8. TUDCA AND INSULIN ACTION
91. 7. TUDCA AND INSULIN ACTION
92. 6. TUDCA AND INSULIN ACTION
93. 5. TUDCA AND INSULIN ACTION
94. 4. TUDCA AND INSULIN ACTION
95. 3. TUDCA AND INSULIN ACTION
96. 2. TUDCA AND INSULIN ACTION
97. 1. TUDCA AND INSULIN ACTION
insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51:771–784

46. Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 2008;20:2180–2197

47. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009;50:1509–1520

48. Bouscarel B, Ceryak S, Gettys TW, Fromm H, Noonan F. Alteration of cAMP-mediated hormonal responsiveness by bile acids in cells of nonhepatic origin. Am J Physiol 1995;268:G908–G916

49. Li N, Hartley DP, Cherrington NJ, Klaassen CD. Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. J Pharmacol Exp Ther 2002;301:551–560